These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30832964)

  • 21. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.
    Shi L; Hodges M; Drummond M; Ahn J; Li SC; Hu S; Augustovski F; Hay JW; Smeeding J
    Value Health; 2010; 13(1):28-33. PubMed ID: 19883403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
    Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
    Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III.
    Mansley EC; Carroll NV; Chen KS; Shah ND; Piech CT; Hay JW; Smeeding J
    Value Health; 2010; 13(1):14-7. PubMed ID: 19883404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preferences for health outcomes and cost-utility analysis.
    Torrance GW
    Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Approaches to Aggregation and Decision Making-A Health Economics Approach: An ISPOR Special Task Force Report [5].
    Phelps CE; Lakdawalla DN; Basu A; Drummond MF; Towse A; Danzon PM
    Value Health; 2018 Feb; 21(2):146-154. PubMed ID: 29477392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health state utilities for economic evaluation of bariatric surgery: A comprehensive systematic review and meta-analysis.
    Xia Q; Campbell JA; Ahmad H; Si L; de Graaff B; Otahal P; Palmer AJ
    Obes Rev; 2020 Aug; 21(8):e13028. PubMed ID: 32497417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report.
    Mandrik OL; Severens JLH; Bardach A; Ghabri S; Hamel C; Mathes T; Vale L; Wisløff T; Goldhaber-Fiebert JD
    Value Health; 2021 Apr; 24(4):463-472. PubMed ID: 33840423
    [No Abstract]   [Full Text] [Related]  

  • 30. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports.
    Taylor RS; Elston J
    Health Technol Assess; 2009 Jan; 13(8):iii, ix-xi, 1-50. PubMed ID: 19203465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
    Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
    Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes measurement: health state preferences and economic evaluation.
    Oldridge NB
    Assist Technol; 1996; 8(2):94-102. PubMed ID: 10163933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].
    Neumann PJ; Willke RJ; Garrison LP
    Value Health; 2018 Feb; 21(2):119-123. PubMed ID: 29477388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validity and interpretation of preference-based measures of health-related quality of life.
    Lenert L; Kaplan RM
    Med Care; 2000 Sep; 38(9 Suppl):II138-50. PubMed ID: 10982099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations.
    Matza LS; Stewart KD; Lloyd AJ; Rowen D; Brazier JE
    Value Health; 2021 Jun; 24(6):812-821. PubMed ID: 34119079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between knee symptoms, change in knee symptoms over 6-9 years, and SF-6D health state utility among middle-aged Australians.
    Singh A; Campbell JA; Venn A; Jones G; Blizzard L; Palmer AJ; Dwyer T; Cicuttini F; Ding C; Antony B
    Qual Life Res; 2021 Sep; 30(9):2601-2613. PubMed ID: 33942204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report.
    Malone DC; Ramsey SD; Patrick DL; Johnson FR; Mullins CD; Roberts MS; Willke RJ; Marshall DA
    Value Health; 2020 Apr; 23(4):409-415. PubMed ID: 32327155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical effectiveness and cost-effectiveness of second-eye cataract surgery: a systematic review and economic evaluation.
    Frampton G; Harris P; Cooper K; Lotery A; Shepherd J
    Health Technol Assess; 2014 Nov; 18(68):1-205, v-vi. PubMed ID: 25405576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of the use of health status measures in economic evaluation.
    Brazier J; Deverill M; Green C; Harper R; Booth A
    Health Technol Assess; 1999; 3(9):i-iv, 1-164. PubMed ID: 10392311
    [No Abstract]   [Full Text] [Related]  

  • 40. Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V.
    Mycka JM; Dellamano R; Kolassa EM; Wonder M; Ghosh S; Hay JW; Smeeding J
    Value Health; 2010; 13(1):25-7. PubMed ID: 19883402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.